Search all CCR Clinical Trials
Below is a list of all open NCI Center for Cancer Research (CCR) clinical trials, including studies that are currently recruiting patients (i.e. Open - Recruiting) as well as trials that will be recruiting soon (i.e., Open - Not yet Recruiting). Most recently opened trials are listed first.
All CCR clinical trials take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.
Clinical trials at the NIH Clinical Center are open to patients with cancer, HIV, or immunodeficiency disorders, regardless of where they live in the United States.
-
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients with Advanced Pancreatic Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0043Investigator Christine Campo Alewine, M.D., Ph.D. -
A Sequential Window of Opportunity Trial of Anti-PD-L1/TGF-ß trap (M7824 ) Alone and in Combination with TriAd Vaccine, and N-803 for p16-Negative Resectable Head and Neck Squamous Cell Carcinoma
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-20-C-0024Investigator Jason M. Redman, M.D. -
A Phase I study of TGF-ß trap (M7824) and NHS-IL12 (M9241) Alone and in Combination with Stereotactic Body Radiation Therapy (SBRT) in Adults with Metastatic Non-Prostate Genitourinary Malignancies
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0012Investigator Andrea B. Apolo, M.D. -
First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects with Metastatic Solid Tumors
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0023Investigator Udo Rudloff, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number -
A Phase 1/2 open-label, multi-center, dose-escalation study of safety, tolerability, pharmacokinetics, dosimetry, and response to repeat dosing of 177Lu-PSMA-R2 radio-ligand therapy in patients with prostate specific membrane antigen (PSMA) positive
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0035Investigator Frank I. Lin, M.D. -
Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0020Investigator Vladimir A. Valera Romero M.D., Ph.D. -
Radium-223 in Biochemically Recurrent Prostate Cancer
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0010Investigator Ravi A. Madan, M.D.Share this trial: Referral ContactsContact Name Phone Number Anna Couvillon 240-858-3148 Ravi Madan 301-480-7168 -
A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0027Investigator Kevin A. Camphausen, M.D. -
Phase I/II trial of PLX038 (PEGylated SN38) and Rucaparib in Solid tumors and Small Cell Cancers.
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0013Investigator Anish Thomas, MBBS, M.D. -
Radium-223 in Biochemically Recurrent Prostate Cancer
Open - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-20-C-0100Investigator Ravi A. Madan, M.D.Share this trial: Referral ContactsContact Name Phone Number Anna Couvillon 240-858-3148 Ravi Madan 301-480-7168 -
Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for Patients with Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sézary Syndrome
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0011Investigator Milos Miljković, M.D., M.Sc. -
Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC).
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0022Investigator Tim F. Greten, M.D. -
Randomized Phase II Trial of Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in Patients with Relapsed Small-Cell Lung Cancer
Open - RecruitingNCI Protocol ID NCI-20-C-0009Investigator Anish Thomas, MBBS, M.D. -
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell malignancies and Hodgkin Lymphoma
Open - RecruitingNCI Protocol ID NCI-20-C-0008Investigator James N. Kochenderfer, M.D. -
Avelumab (Bavencio) with IL-15 in subjects with clear-cell renal carcinoma
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0007Investigator Kevin C. Conlon, M.D. -
A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC).
Open - Not yet RecruitingNCI Protocol ID NCI-20-C-0006Investigator Tim F. Greten, M.D. -
Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients with Advanced Cancer
Open - RecruitingNCI Protocol ID NCI-20-C-0001Investigator Marijo Bilusic, M.D., Ph.D. -
A Phase II Study Using the Administration of Autologous T-Cells Engineered using the Sleeping Beauty Transposon/Transposase System to Express T-Cell Receptors Reactive Against Mutated Neoantigens in Patients with Metastatic Cancer
Open - RecruitingNCI Protocol ID NCI-19-C-0143Investigator Steven A. Rosenberg, M.D., Ph.D.Share this trial: Referral ContactsContact Name Phone Number Immunotherapy Recruitment Center 866-820-4505 -
Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Open - Not yet RecruitingNCI Protocol ID NCI-19-C-0138Investigator Frank I. Lin, M.D. -
Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors
Open - RecruitingNCI Protocol ID NCI-19-C-0137Investigator Andrea B. Apolo, M.D.Share this trial: Referral ContactsContact Name Phone Number